Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Faith Gebhardt

Physician Assistant Raleigh, NC Physician Assistant

NPI 1023575420 CMS profile 10860329

1540 Sunday Dr, Raleigh, NC 27607

Open in the dashboard

General payments

$20,391

130 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Faith Gebhardt of Raleigh, NC is reported in the CMS Open Payments database as having received $20,391 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,229 47
2024 General $13,152 57
2023 General $5,950 22
2022 General $30 2
2021 General $30 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Faith Gebhardt
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Faith Gebhardt were reported at $1,229. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Faith Gebhardt Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $30 $132 $37–$438 $132
2022 $30 $155 $48–$522 $149
2023 $5,950 $167 $52–$557 $160
2024 $13,152 $178 $55–$600 $164
2025 $1,229 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $13,414 59 payments
  2. Relievant Medsystems, Inc. $5,930 21 payments
  3. AbbVie, Inc. $391 23 payments
  4. Lundbeck LLC $111 4 payments
  5. Axsome Therapeutics, Inc. $100 5 payments
  6. Janssen Biotech, Inc. $92 2 payments
  7. UCB, Inc. $84 3 payments
  8. Amgen Inc. $80 5 payments
  9. ACADIA Pharmaceuticals Inc $51 2 payments
  10. Pfizer Inc. $45 2 payments
  11. Other $92 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,035 36 payments
  2. Travel and Lodging $4,979 17 payments
  3. Food and Beverage $3,300 76 payments
  4. Education $77 1 payment
Products named General payments · program years 2021–2025
  1. Intracept Pain $10,139 44 payments
  2. Intracept Pain $5,930 21 payments
  3. Intracept Pain $5,930 21 payments
  4. Intracept Pain $5,930 21 payments
  5. QULIPTA $351 21 payments
  6. UBRELVY $347 21 payments
  7. Intracept Contains (1)Intracept RF Probe (2)Intracept Access Instruments_NMOD $263 2 payments
  8. VYEPTI $111 4 payments
  9. Symbravo $100 5 payments
  10. Nayzilam $84 3 payments
  11. Other $365 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,599

Median for Physician Assistant: 241

Drug cost

$19,264

Median for Physician Assistant: $4,110

Branded share of claims

4.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 468 $6,245
Duloxetine Hcl Generic 184 $2,969
Pregabalin Generic 106 $2,765
Amitriptyline Hcl Generic 258 $2,379
Celecoxib Generic 82 $1,511
Ibandronate Sodium Generic 15 $645
Diclofenac Sodium Generic 42 $374
Cyclobenzaprine Hcl Generic 45 $357
Baclofen Generic 60 $325
Meloxicam Generic 76 $320

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$210,633

Of which drugs: $111,544

Medicare patients

560

Average age 75

Services billed

10,963

371 women, 189 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Depression 29%
Diabetes 28%
Osteoporosis 27%
Atrial fibrillation 18%
Chronic kidney disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 27 2,640 $54,038

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record